VIAF

Virtual International Authority File

Search

Leader     00000nz a2200037n 45 0
001     WKP|Q83242683  (VIAF cluster)  (Authority/Source Record)
003     WKP
005     20241120235944.0
008     241120nneanz||abbn n and d
035 ‎‡a  (WKP)Q83242683‏
024 ‎‡a  0000-0003-1059-8344‏ ‎‡2  orcid‏
035 ‎‡a  (OCoLC)Q83242683‏
100 0 ‎‡a  Maren de Vries‏ ‎‡c  researcher‏ ‎‡9  en‏
400 0 ‎‡a  Maren de Vries‏ ‎‡c  wetenschapper‏ ‎‡9  nl‏
670 ‎‡a  Author's A cholesterol consensus motif is required for efficient intracellular transport and raft association of a group 2 HA from influenza virus‏
670 ‎‡a  Author's A severe equine herpesvirus type 1‏
670 ‎‡a  Author's A severe equine herpesvirus type 1 (EHV-1) abortion outbreak caused by a neuropathogenic strain at a breeding farm in northern Germany.‏
670 ‎‡a  Author's Identification of a nerve-associated, lung-resident interstitial macrophage subset with distinct localization and immunoregulatory properties‏
670 ‎‡a  Author's LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection‏
670 ‎‡a  Author's Mutation of a raft-targeting signal in the transmembrane region retards transport of influenza virus hemagglutinin through the Golgi.‏
670 ‎‡a  Author's The ETS transcription factor ELF1 regulates a broadly antiviral program distinct from the type I interferon response‏
670 ‎‡a  Author's The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates‏
670 ‎‡a  Author's The NSP14/NSP10 RNA repair complex as a Pan-coronavirus therapeutic target‏
909 ‎‡a  (orcid) 0000000310598344‏ ‎‡9  1‏
919 ‎‡a  mutationofarafttargetingsignalinthetransmembraneregionretardstransportofinfluenzavirushemagglutininthroughthegolgi‏ ‎‡A  Mutation of a raft-targeting signal in the transmembrane region retards transport of influenza virus hemagglutinin through the Golgi.‏ ‎‡9  1‏
919 ‎‡a  lycov555arapidlyisolatedpotentneutralizingantibodyprovidesprotectioninanonhumanprimatemodelofsarscov2infection‏ ‎‡A  LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection‏ ‎‡9  1‏
919 ‎‡a  identificationofanerveassociatedlungresidentinterstitialmacrophagesubsetwithdistinctlocalizationandimmunoregulatoryproperties‏ ‎‡A  Identification of a nerve-associated, lung-resident interstitial macrophage subset with distinct localization and immunoregulatory properties‏ ‎‡9  1‏
919 ‎‡a  severeequineherpesvirustype1ehv1abortionoutbreakcausedbyaneuropathogenicstrainatabreedingfarminnortherngermany‏ ‎‡A  A severe equine herpesvirus type 1 (EHV-1) abortion outbreak caused by a neuropathogenic strain at a breeding farm in northern Germany.‏ ‎‡9  1‏
919 ‎‡a  severeequineherpesvirustype1‏ ‎‡A  A severe equine herpesvirus type 1‏ ‎‡9  1‏
919 ‎‡a  nsp14nsp10rnarepaircomplexasapancoronavirustherapeutictarget‏ ‎‡A  The NSP14/NSP10 RNA repair complex as a Pan-coronavirus therapeutic target‏ ‎‡9  1‏
919 ‎‡a  etstranscriptionfactorelf1regulatesabroadlyantiviralprogramdistinctfromthetype1interferonresponse‏ ‎‡A  The ETS transcription factor ELF1 regulates a broadly antiviral program distinct from the type I interferon response‏ ‎‡9  1‏
919 ‎‡a  neutralizingantibodylycov555protectsagainstsarscov2infectioninnonhumanprimates‏ ‎‡A  The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates‏ ‎‡9  1‏
919 ‎‡a  cholesterolconsensusmotifisrequiredforefficientintracellulartransportandraftassociationofagroup2hafrominfluenzavirus‏ ‎‡A  A cholesterol consensus motif is required for efficient intracellular transport and raft association of a group 2 HA from influenza virus‏ ‎‡9  1‏
996 ‎‡2  LC|no2022042248‏
996 ‎‡2  ISNI|0000000057608077‏
996 ‎‡2  PLWABN|9810662870305606‏
996 ‎‡2  ISNI|0000000036038984‏
996 ‎‡2  NTA|118670654‏
996 ‎‡2  NTA|155386522‏
996 ‎‡2  ISNI|0000000397033273‏
996 ‎‡2  NTA|204371074‏
996 ‎‡2  NTA|180725459‏
996 ‎‡2  ISNI|0000000387240885‏
996 ‎‡2  NTA|314431861‏
996 ‎‡2  NTA|28560015X‏
996 ‎‡2  ISNI|0000000395055954‏
996 ‎‡2  NTA|236455400‏
996 ‎‡2  NTA|353982636‏
996 ‎‡2  ISNI|0000000391178949‏
996 ‎‡2  NUKAT|n 2012263092‏
996 ‎‡2  DNB|1199310816‏
996 ‎‡2  NTA|069861447‏
996 ‎‡2  ISNI|0000000025165195‏
996 ‎‡2  NTA|395442958‏
996 ‎‡2  ISNI|0000000419503767‏
996 ‎‡2  NTA|326498613‏
996 ‎‡2  ISNI|0000000394713265‏
996 ‎‡2  NTA|069852715‏
996 ‎‡2  ISNI|000000041980915X‏
996 ‎‡2  ISNI|0000000419440444‏
996 ‎‡2  ISNI|0000000387742666‏
996 ‎‡2  DNB|12736742X‏
996 ‎‡2  NTA|126030073‏
996 ‎‡2  NTA|395147220‏
996 ‎‡2  ISNI|0000000022865938‏
996 ‎‡2  ISNI|0000000398564471‏
996 ‎‡2  NTA|151499829‏
996 ‎‡2  NTA|333159586‏
996 ‎‡2  ISNI|0000000395201296‏
996 ‎‡2  DNB|1053260342‏
996 ‎‡2  NTA|387509240‏
996 ‎‡2  ISNI|0000000397020712‏
996 ‎‡2  ISNI|0000000396588509‏
996 ‎‡2  ISNI|0000000368922768‏
996 ‎‡2  NTA|072078480‏
996 ‎‡2  ISNI|0000000395406849‏
996 ‎‡2  NTA|344687821‏
996 ‎‡2  NTA|163196796‏
996 ‎‡2  ISNI|0000000419563516‏
996 ‎‡2  ISNI|0000000390696445‏
996 ‎‡2  NUKAT|n 2021125918‏
996 ‎‡2  ISNI|0000000389362448‏
996 ‎‡2  BNF|17978886‏
996 ‎‡2  NTA|326919430‏
996 ‎‡2  NTA|068961286‏
996 ‎‡2  ISNI|0000000452595018‏
996 ‎‡2  ISNI|0000000393412479‏
996 ‎‡2  ISNI|0000000041935460‏
996 ‎‡2  LC|no2024066673‏
996 ‎‡2  SUDOC|050310917‏
996 ‎‡2  ISNI|0000000034506801‏
996 ‎‡2  NTA|364185198‏
996 ‎‡2  ISNI|000000010866394X‏
996 ‎‡2  NTA|075080710‏
996 ‎‡2  ISNI|000000039850679X‏
996 ‎‡2  PLWABN|9810611347505606‏
996 ‎‡2  NUKAT|n 2010110424‏
996 ‎‡2  NTA|08137660X‏
996 ‎‡2  NTA|236201816‏
996 ‎‡2  NTA|292380097‏
996 ‎‡2  ISNI|0000000398574872‏
996 ‎‡2  NTA|333583930‏
996 ‎‡2  ISNI|0000000393108282‏
996 ‎‡2  NTA|069730318‏
996 ‎‡2  NTA|13361512X‏
996 ‎‡2  ISNI|0000000387080148‏
996 ‎‡2  ISNI|0000000452670639‏
996 ‎‡2  NTA|304080802‏
996 ‎‡2  NTA|215634063‏
996 ‎‡2  NTA|32651628X‏
996 ‎‡2  CAOONL|ncf11358400‏
996 ‎‡2  ISNI|0000000387339535‏
996 ‎‡2  NTA|163225796‏
996 ‎‡2  NTA|241860822‏
996 ‎‡2  LC|n 85255006‏
996 ‎‡2  ISNI|0000000395276247‏
996 ‎‡2  ISNI|0000000392803056‏
996 ‎‡2  ISNI|0000000035447858‏
996 ‎‡2  NTA|125335598‏
996 ‎‡2  LC|no2001017543‏
996 ‎‡2  BNF|13524063‏
996 ‎‡2  NTA|132851393‏
996 ‎‡2  ISNI|0000000452526522‏
996 ‎‡2  ISNI|0000000109567060‏
996 ‎‡2  NTA|144851733‏
996 ‎‡2  ISNI|0000000079704051‏
996 ‎‡2  NTA|183352890‏
996 ‎‡2  NTA|112060242‏
996 ‎‡2  NTA|072454830‏
996 ‎‡2  NTA|355566370‏
996 ‎‡2  ISNI|0000000040147593‏
996 ‎‡2  ISNI|000000008083817X‏
996 ‎‡2  ISNI|0000000391244379‏
996 ‎‡2  ISNI|000000038887066X‏
996 ‎‡2  ISNI|0000000387573006‏
996 ‎‡2  NTA|304121584‏
996 ‎‡2  ISNI|0000000387620781‏
996 ‎‡2  NTA|395481805‏
996 ‎‡2  NTA|393739732‏
996 ‎‡2  BIBSYS|90559118‏
996 ‎‡2  ISNI|0000000393894164‏
996 ‎‡2  BIBSYS|90639652‏
996 ‎‡2  ISNI|0000000026979449‏
996 ‎‡2  NTA|073158771‏
996 ‎‡2  NTA|41712841X‏
996 ‎‡2  ISNI|0000000443764377‏
996 ‎‡2  RERO|A000048716‏
996 ‎‡2  ISNI|0000000390200542‏
996 ‎‡2  BNF|13526515‏
996 ‎‡2  ISNI|000000039606975X‏
996 ‎‡2  NTA|241860849‏
996 ‎‡2  ISNI|0000000397018743‏
996 ‎‡2  ISNI|0000000031732168‏
996 ‎‡2  NTA|322973767‏
996 ‎‡2  ISNI|0000000014832378‏
996 ‎‡2  NTA|318094126‏
996 ‎‡2  NTA|176691278‏
996 ‎‡2  ISNI|0000000391001676‏
996 ‎‡2  NTA|110251458‏
996 ‎‡2  NTA|072028343‏
997 ‎‡a  0 0 lived 0 0‏ ‎‡9  1‏
998 ‎‡a  Vries, Maren ˜deœ‏ ‎‡2  DNB|107985469X‏ ‎‡3  title: (0.71, 'influenzavirushemagglutinincontainsacholesterolconsensusmotifrequiredforefficientintracellulartransportandlipidraftintegration', 'cholesterolconsensusmotifisrequiredforefficientintracellulartransportandraftassociationofagroup2hafrominfluenzavirus')‏